James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

What’s the Real Impact of Generic Drugs?

The danger of patent expirations for big pharma isn't new, but the amount of market share those brands are losing to generics as a result are not pretty.

Verizon vs. AT&T: Which Should You Buy?

Stodgy telecoms AT&T and Verizon both have had fantastic returns this year, but one looks prepped to start eating away at the other.

Tire Manufacturers Finally Ready to Roll

The shipping industry is busier and rubber prices are tanking, creating the perfect storm for tire manufacturers -- and their investors -- to make some money.

Who Fits Into Microsoft’s Surface Ecosystem?

If Microsoft's Surface tablet is able to get legs, a number of stocks not tickered MSFT could enjoy a bump, while others might suffer collateral damage.

5 of Pharma’s Most Disastrous Drug Approvals

These five exciting drug approvals now serve as warning stories about the potential pitfalls for investors trying to time a pharma stock buy.